The Festival of Biologics in San Diego is over, and I have one last day of meetings with partners left before I make my way back to the UK. Some productive meetings have been had. #apta

It's great to see some confidence in the company being represented in positive share price movement. Things have been a bit quiet on the RNS front, but things are moving along in the background. As previously announced, we are in late-stage discussions across multiple deals, and

linkedin.com/posts/the-apta…

We have licensed Optimers with proven function as vaccine adjuvants to the University of Glasgow, with agreed royalties of 10% for Aptamer on all Optimer-containing vaccines. londonstockexchange.com/news-article/A… #APTA #Optimer

In partnership with Neuro-Bio Ltd, Aptamer has converted the test for Alzheimer's to a common hospital format and agreed licensing of a 11.1% blended royalty rate on sales of this clinical diagnostic format. londonstockexchange.com/news-article/A… #APTA #diagnostics #Alzheimers

Join our team next week at #ASGCT! Meet them at booth 714 to find out how Optimer can help with: 🎯Targeted delivery for your gene therapy 🧪Custom reagents 🔍 Identify new biomarkers of disease #ASGCT #drugdelivery #genetherapy #celltherapy #AGSCT2025

prnewswire.com/news-releases/…

Today we announce the agreement of the second Optimer development programme with Unilever, to expand Optimer applications in personal care. polaris.brighterir.com/public/aptamer…

link.springer.com/article/10.100…

All smiles at the off! Our CEO, Arron, and CFO, Andrew Rapson are ready for a busy #BIO2025 discussing the latest in non-viral delivery systems. Meeting old friends and new, they have a busy week planned. Lots of coffee guys! ☕

#BIO2025 lots of exciting meetings had so far. It’s always great to catch up with collaborators and potential partners to develop exciting scientific solutions.

Illumina’s $350M buy of SomaLogic boosts aptamer tech. SomaScan’s protein profiling with Illumina’s NGS advances multiomics. As an aptamer geek, I’m excited for its biomarker potential and further validation of aptamer technology. #Proteomics #Aptamers illumina.com/company/news-c…

Our new agreement with a global life science leader is to develop Optimer-Fc reagents for immunohistochemistry. Find out more here: polaris.brighterir.com/public/aptamer…

Interesting report out. transparencymarketresearch.com/aptamers-marke…

A significant advance in our liver fibrosis program with: ✅ identification of a novel biomarker targeted by the Optimer ✅ evidence of Optimer reducing scar tissue formation Read more: polaris.brighterir.com/public/aptamer…

We have successfully raised £2M. This will accelerate: - Licensing discussions - Manufacturing - Biomarker discovery service launch - Animal models for liver fibrosis delivery - AI/ML integration into Optimer londonstockexchange.com/news-article/A…

Today, we announced a £2M fundraise, which will bolster our balance sheet for licensing negotiations on key assets. We will invest in capital equipment for asset manufacturing to meet supply demands and support animal model work for potential liver disease therapies. The success

💡💥 ICYMI, we have identified a novel target on HSCs to enable 🎯cell-specific gene therapy for liver fibrosis 🧬🧠 selectscience.net/article/aptame…